Cited 1 times since 1987 (0 per year) source: EuropePMC European journal of cancer & clinical oncology, Volume 23, Issue 8, 1 1 1987, Pages 1207-1208 Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer. Postmus PE, Mulder NH, Grampel JC, Meyers WH, Berendsen HH
Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC.
